Sterling Capital Management
PRME icon

Sterling Capital Management’s Prime Medicine PRME Stock Holding History

Sterling Capital Management’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$8.93K Buy
2,922
+2,386
+445% +$7.93K ﹤0.01% 2579
2026
Q2 		$1.98K Sell
536
-2,926
-85% -$9.7K ﹤0.01% 2995
2026
Q1 		$12K Sell
3,462
-2,274
-40% -$8.66K ﹤0.01% 2277
2025
Q4 		$19.9K Buy
5,736
+542
+10% +$2.41K ﹤0.01% 2230
2025
Q3 		$28.8K Buy
5,194
+3,618
+230% +$14.7K ﹤0.01% 1978
2025
Q2 		$3.89K Buy
1,576
+1,518
+2,617% +$2.34K ﹤0.01% 2649
2025
Q1 		$115 Hold
58
– – ﹤0.01% 3132
2024
Q4 		$169 Hold
58
– – ﹤0.01% 3133
2024
Q3 		$224 Buy
+58
New +$269 ﹤0.01% 3098

Other funds holding PRME

Alphabet Inc
Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Alessandra Capital Management
Alessandra Capital Management Torrance, California $142M AUM 42.73% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Green Alpha Advisors
Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return

Sterling Capital Management's PRME Position: Q3 2026 in Review

Sterling Capital Management increased its Prime Medicine (PRME) stake by 445% in Q3 2026, buying an estimated $7.93K and bringing the position to 2,922 shares worth $8.93K. The position accounts for ﹤0.01% of the portfolio, ranked #2579.

Sterling Capital Management first reported a position in PRME in Q3 2024 and has held it in 9 quarters since. The position peaked at $28.8K in Q3 2025. 62 funds tracked by Wall St. Rank hold PRME as of Q3 2026.

  • Sterling Capital Management held 2,922 shares of Prime Medicine worth $8.93K as of Q3 2026.
  • Sterling Capital Management bought 2,386 Prime Medicine shares in Q3 2026, an estimated $7.93K.
  • Prime Medicine made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #2579 holding.
  • Sterling Capital Management first reported a position in Prime Medicine in Q3 2024 and has held it in 9 quarters since.
  • Sterling Capital Management's Prime Medicine position peaked at $28.8K in Q3 2025.
  • 62 funds tracked by Wall St. Rank held Prime Medicine as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.